-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 11, Merck announced that it had submitted an emergency authorization application (EUA) for the oral antiviral drug Molnupiravir (MK-4482) to the FDA
From: Merck official website
The EUA is based on the positive interim analysis results of the Phase 3 clinical MOVe-OUT study
In terms of safety, the incidence of any adverse events in the Molnupiravir group and the placebo group was similar (35% and 40%, respectively), and the incidence of drug-related adverse events was also the same (12% and 11%, respectively)
At the beginning of this year, Merck has reached a procurement agreement with the US government